Risperidone Tablet
NDC Package 42291-910-60
Package Information
Risperidone tablets is risperidone is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This formulation utilizes a tablet delivery system. Marketed by Avkare, this product is identified by NDC 42291-910 and is authorized under FDA application ANDA078071.
Identification & Billing
- RxCUI: 312828 - risperiDONE 0.25 MG Oral Tablet
- RxCUI: 312828 - risperidone 0.25 MG Oral Tablet
- RxCUI: 312829 - risperiDONE 0.5 MG Oral Tablet
- RxCUI: 312829 - risperidone 0.5 MG Oral Tablet
- RxCUI: 312830 - risperiDONE 1 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 42291 - Avkare
- 42291-910 - Risperidone
- 42291-910-60 - 60 TABLET in 1 BOTTLE
- 42291-910 - Risperidone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (42291-910). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42291-910-60 identifies a specific commercial package of 60 tablet in 1 bottle of Risperidone, a human prescription drug labeled by Avkare. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This tablet is formulated for oral use and contains risperidone as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avkare on September 10, 2021. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Risperidone is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This medication can help you to think clearly and take part in everyday life. Risperidone belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.
How is this Avkare product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42291091060. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.